Compugen (Compugen) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Compugen FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Compugen's Free Cash Flow for the three months ended in Dec. 2023 was $0.00 Mil. Compugen's Revenue for the three months ended in Dec. 2023 was $33.46 Mil. Therefore, Compugen's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Compugen's current FCF Yield % is -20.19%.

The historical rank and industry rank for Compugen's FCF Margin % or its related term are showing as below:

CGEN' s FCF Margin % Range Over the Past 10 Years
Min: -3149.14 Med: -346.36 Max: -75.56
Current: -107.77

During the past 13 years, the highest FCF Margin % of Compugen was -75.56%. The lowest was -3149.14%. And the median was -346.36%.

CGEN's FCF Margin % is ranked better than
53.92% of 1033 companies
in the Biotechnology industry
Industry Median: -148.24 vs CGEN: -107.77

Compugen FCF Margin % Historical Data

The historical data trend for Compugen's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compugen FCF Margin % Chart

Compugen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-1,424.30

-383.05

-461.33

-107.77

Compugen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Compugen's FCF Margin %

For the Biotechnology subindustry, Compugen's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Compugen's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Compugen's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Compugen's FCF Margin % falls into.

Compugen FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Compugen's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-36.058	/	33.459
	=	-107.77 %

Compugen's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0	/	33.459
	=	0.00 %

Compugen FCF Margin % Related Terms

Thank you for viewing the detailed overview of Compugen's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Compugen (Compugen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compugen Ltd (NAS:CGEN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

CGEN:Israel

Address

26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849

Website

https://www.cgen.com

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.